Sinovac Biotech, Ltd. - Ordinary Shares (Antigua/Barbudo) (SVA) analyst actions
Rating and price-target actions on SVA in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the SVA overview →
1 measured SVA analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD) | Press release | — | — |
Keep exploring
More SVA: earnings → · SEC filings → · SVA overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| BioPlus Acquisition Corp. (BIOS) | 822 | 0.00% | 47% |
| CYTRX CORP (CYTR) | 821 | -0.00% | 43% |
| Atara Biotherapeutics, Inc. (ATRA) | 813 | -0.27% | 45% |
| Ionis Pharmaceuticals, Inc. (IONS) | 811 | +0.02% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.